BBA
IMVT icon

Baker Bros. Advisors’s Immunovant IMVT Stock Holding History

Baker Bros. Advisors’s Portfolio IMVT Stock Details IMVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$209M Sell
5,435,220
-22,661
-0.4% -$690K 1.05% 16
2026
Q1 		$136M Hold
5,457,881
– – 0.78% 18
2025
Q4 		$139M Hold
5,457,881
– – 0.81% 18
2025
Q3 		$88M Hold
5,457,881
– – 0.64% 20
2025
Q2 		$87.3M Hold
5,457,881
– – 0.85% 15
2025
Q1 		$93.3M Buy
5,457,881
+3,750,000
+220% +$78.4M 1.03% 14
2024
Q4 		$42.3M Buy
1,707,881
+482,471
+39% +$13.7M 0.45% 29
2024
Q3 		$34.9M Buy
1,225,410
+760,692
+164% +$22.4M 0.36% 30
2024
Q2 		$12.3M Buy
464,718
+39,709
+9% +$1.13M 0.16% 45
2024
Q1 		$13.7M Hold
425,009
– – 0.17% 42
2023
Q4 		$17.9M Hold
425,009
– – 0.2% 39
2023
Q3 		$16.3M Buy
+425,009
New +$9.61M 0.09% 40

Other funds holding IMVT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Baker Bros. Advisors's IMVT Position: Q2 2026 in Review

Baker Bros. Advisors reduced its Immunovant (IMVT) stake by 0.42% in Q2 2026, selling an estimated $690K and leaving 5,435,220 shares worth $209M. The position accounts for 1.05% of the portfolio, ranked #16.

Baker Bros. Advisors first reported a position in IMVT in Q3 2023 and has held it in 12 quarters since. 226 funds tracked by Wall St. Rank hold IMVT as of Q2 2026.

  • Baker Bros. Advisors held 5,435,220 shares of Immunovant worth $209M as of Q2 2026.
  • Baker Bros. Advisors sold 22,661 Immunovant shares in Q2 2026, an estimated $690K.
  • Immunovant made up 1.05% of Baker Bros. Advisors's portfolio in Q2 2026, its #16 holding.
  • Baker Bros. Advisors first reported a position in Immunovant in Q3 2023 and has held it in 12 quarters since.
  • 226 funds tracked by Wall St. Rank held Immunovant as of Q2 2026.

Based on Baker Bros. Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.